Citizens maintains Iovance Biotherapeutics at Market Outperform, raises price target to $12 from $8
Citizens maintained Iovance Biotherapeutics at Market Outperform, raising its price target to $12 from $8, implying a 55% upside from the Nov 5 close of $7.74. Recent analyst price targets for the company range from $8 to $18.
How this was made

The 30-second read
Why it matters
The upgrade may attract new buyers and support the stock price.
Market read
Analyst target raise could influence short-term trading activity in IOVN.
What to watch
No new clinical data released; the upgrade is based on analyst opinion alone.
Background
Citizens' analyst note updates the price target for Iovance Biotherapeutics.
Market effects
May lift sentiment for the broader biotech sector.
Limited to U.S. biotech investors.
Low
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- Analyst FirmCitizens
Provided the price target upgrade.
- CompanyIovance Biotherapeutics
Biotech company receiving the upgraded target.



